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1. Introduction
In developed countries, most studies reveal that the number of people who develop brain
tumors and die from them has increased. Brain tumor, one of the most devastating central
nervous system pathologies, is the leading cause of solid tumor death in children under the
age of 15, and the second leading cause of cancer death in male adults ages 20-39. So far,
researches on genesis and development of tumor are intensively focused and studied on
alteration of the gene in nucleus and brain tumors is the one where most were reported arise
as the result of progressive nuclear genetic alterations. Multiple genetic events have been
identified in brain tumor cells involving some well-known susceptibility genes such as tumor
suppressor and oncogenes that are encoded by the nuclear DNA (nDNA). For instance, the
p53 tumor suppressor gene is frequently mutated and often detected altered or lost early in
brain tumor mainly in astrocytic tumors formation [1-3]. Similarly, mutations or loss of PTEN
(phosphatase and tensin homolog), p16, RB (retinoblastoma) and amplification of EGFR
(epidermal growth factor receptor), MDM2, CDK4, CDK6 (cyclin-dependent kinase) are also
involved in the pathogenesis of brain tumor [4,5].
Although, it is well established that multiple alterations in the nuclear-encoded genes are
associated with tumor development, it is reasonable to consider and postulate that there is
another factor or genome yet to be investigated. The involvement of the mitochondrial genome
in tumorigenesis and cancer progression remains controversial to date. Mitochondria are
cytoplasmic organelles in eukaryotic cell and recognized as “the power houses of the cell”,
thus one of their principal functions is providing cellular energy, adenosine triphosphate
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(ATP) through the oxidative phosphorylation (OXPHOS) [6]. OXPHOS can be defined as the
oxidation of electron transfer chain by oxygen and the concomitant transduction of this energy
into ATP. The OXPHOS system is composed of five protein complexes: NADH-ubiquinone
oxidoreductase as complex I, succinate-ubiquinone oxidoreductase as complex II, ubiquinone-
cytochrome c oxidoreductase as complex III, cytochrome c oxidase as complex IV and ATP
synthase as complex V.
In addition to energy production, mitochondria are also key components in calcium signalling,
regulation of cellular metabolism, haem synthesis, steroid synthesis and, perhaps most
importantly, the initiation and execution of apoptosis [7,8]. Over the last 25 years, mitochon‐
drial abnormalities that associated with mitochondrial DNA (mtDNA) alterations, has been
identified in human disease, including seizure, ataxia, ophthalmoplegia, optic atrophy, short
stature, sensorineural hearing loss, cardiomyopathy, diabetes mellitus and kidney failure
[9,10]. Accumulation of altered mtDNA has also been widely believed to play the pivotal role
in aging and the development of various age-related degenerative diseases [11]. In recent years,
more attention has been directed towards the role of mitochondrial dysfunction in various
cancer due to genetic defects of OXPHOS system [12-17]. Proteins that take part in the proper
functioning of the OXPHOS system are encoded by both nDNA and mtDNA. Similar to nDNA,
mtDNA mutations and deletions have been identified in a wide variety of cancers including
brain tumor [18-26], although it is unclear whether these are causal or a consequence of the
neoplastic process.
This chapter begins with a general overview of basic mitochondrial structure and OXPHOS
system functions and then outlines more specifically the link between mitochondrial reactive
oxygen spices (ROS) and apoptosis with tumorigenesis and genetic alterations in mitochondria
associated with human cancers mainly brain tumor.
2. Mitochondrial structure
Mitochondria are seen by electron microscopy to be intracellular oblong or ovoid shaped
organelles with a transverse diameter of 0.1-0.5 µm and a variable length [27]. The structure
of mitochondria is shown in Figure 1. Most eukaryotic cells contain many mitochondria, which
cover up to 25% of the volume of the cytoplasm. The number of mitochondria within a cell
increases with the amount of substrate and oxygen. Mitochondria are large enough to be
observed under a light microscope, but the detail of their structure can be viewed only with
the electron microscope.
Initial studies based on electron microscopy investigations by two researchers Palade and
Sjöstrand, revealed that mitochondria contain more than one membrane system with the
existence of an outer membrane and of a highly folded inner membrane [28,29]. The baffle
model which was coined by Palade has been accepted and currently depicted as a model of
mitochondria structure in all the textbooks [28]. The baffle model describes mitochondria as
having four compartments (Figure 1). The first compartment is termed the outer membrane.
This smooth membrane surrounds with a very convoluted or folded inner membrane. The
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inner membrane is folded to create cristae. The outer and inner membranes have very different
properties. Together they create two compartments, namely the intermembrane space (the
space between the outer and inner membranes), and the matrix (closed by the inner membrane-
the very interior of the mitochondria).
Nowadays, the baffle model has been shown to be inaccurate. Based on the investigations of
3-D structure of mitochondrial morphology by electron microscope tomography, the inner
membrane is believed to be further divided into two distinct domains: an inner boundary
membrane and cristae membranes [27, 30-32]. The inner boundary membrane is located close
to the outer membrane and makes close contact with it at numerous positions. Cristae
membranes protrude into the matrix compartment and are connected to the inner boundary
membrane by narrow tubular structures called cristae junctions.
The outer bilayer lipid membrane contains channels made of voltage dependent anion
channels called porins and are permeable to molecules < 10,000 Da. It is composed of approx‐
imately 50% lipids and 50% proteins. The inner bilayer lipid membrane is folded and imper‐
meable to most molecules and protons. It is built up of 70% protein. The inner membrane is
also the site of the electron transport chain and contains transport proteins for OXPHOS
system. Within the matrix a large number of enzymes and other proteins and peptides,
including DNA-polymerase, chaperones (heat shock proteins), ribosomes, mRNAs, tRNAs,
and the mtDNA are located.
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Inter-membrane space
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Figure 1. The structure of a mitochondrion
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3. Mitochondrial function: OXPHOS system
Mitochondria play a central role in energy conversion processes (respiration) within the cell
through the electron transport chain, the primary function of which is ATP synthesis via a
complex mechanism referred to as “oxidative phosphorylation” (OXPHOS) (Figure 2).
OXPHOS is the production of ATP using energy derived from the transfer of electrons in an
electron transport system and occurs by chemiosmosis. As the process of mitochondrial
electron transport takes place, energy is released in the form of a proton electrochemical
gradient that can be used to make ATP. Though, the details regarding the conservation of this
released energy are still being debated, most scientists accept the chemiosmotic hypothesis as
the general mechanism for the energy transfer. The chemiosmotic hypothesis was formulated
in the 1960s by Peter Mitchell [33,34]. This hypothesis states that hydrogen ions (H+or protons)
are transferred from mitochondrial matrix out across the inner membrane to the inter-
membrane space as electron transport occurs by a series of reduction-oxidation reactions that
establish an electrochemical gradient. The membrane is impermeable to protons, which flow
back down the proton gradient through a large enzyme called ATP synthase or complex V,
the energy from which is subsequently used to produce ATP.
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Figure 2. A schematic representation of the mitochondrial OXPHOS system
For achieving the whole process, in first stage pyruvate, which is generated in the cytosol
during glycolysis, is transported across the double mitochondrial membranes and enters the
matrix. The pyruvate molecules are produced by the breakdown of glucose molecules from
carbohydrates via glycolysis. Once inside the matrix, pyruvate molecules are converted to the
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two carbon compound acetyl coenzyme A (acetyl CoA). This oxidative decarboxylation
reaction is catalyzed by the pyruvate dehydrogenase complex. The acetyl CoA is then taken
into a sequence of enzymatically catalyzed reactions known as the citric acid cycle which
completes the oxidation of carbon and regenerates an electron acceptor to keep the cycle going.
The oxidation of acetyl CoA in the citric acid cycle (which is also called the Krebs cycle or
tricarboxylic acid cycle) is catalyzed by a set of enzymes localized in the mitochondrial matrix.
During this process, the released electrons are transferred to co-enzymes, NAD+and FAD to
form the reduced molecules NADH and FADH2. Later, NADH and FADH2 transfer electrons
to acceptor molecules in the electron transport chain, in the inner mitochondrial membrane.
Coenzyme Q (ubiquinone) and cytochrome c are also involved in mitochondrial respiration,
serving as ‘electron shuttles’ or mobile electron carriers between the complexes.
Electrons donated from NADH to Complex I or from FADH2 to Complex II are passed to
coenzyme Q. Electrons then flow from coenzyme Q to Complex III which transfers the electrons
to cytochrome c. From cytochrome c the electrons move to Complex IV and finally to ½ O2 to
produce H2O [35]. As electrons pass through these complexes in a series of oxidation-reduction
reactions, the energy that is released by this electron transport chain is used to pump protons
out from the mitochondrial matrix to the inter membrane space via Complexes I, III and IV
creating the electrochemical gradient. The electrochemical gradient allows protons to drive
back into the matrix through a pore in Complex V (ATP synthase), using the released energy
to catalyze the synthesis of ATP from ADP and phosphate.
4. Mitochondrial genome
Mitochondria have a genetic system of their own, separate from the nuclear one, with all the
machinery necessary for its expression; that is, to replicate, transcribe and translate the genetic
information they contain. The mitochondrial deoxyribonucleic acid (mtDNA) was discovered
in 1963 [36] and the near complete sequence for human mtDNA was available in 1981 [37] and
was minimally revised in 1999 [38]. Human mtDNA is mostly a double-stranded, closed
circular molecule composed of 16,569 base pairs.
Figure 3 shows the human mitochondrial genome. It is very compact, containing little non-
coding sequence, essentially just the 1.1 kb D-loop (displacement loop or non-coding) region,
and having even some overlapping genes. The non-coding region that includes the D-loop is
located between genes encoding tRNA phenylalanine (F) and proline (P). The two strands of
mtDNA have been named light strand (L-strand, rich in cytosines) and heavy strand (H-strand,
rich in guanines) according to their buoyancy through a denaturing caesium chloride gradient
[39].
The D-loop region of mtDNA contains the origin of replication for H-strand synthesis as well
as both mitochondrial transcription promoters (the light strand promoter, LPS and two heavy
strand promoters, HSP1 and HSP2), and serves as the main site for mitochondrial genomic
replication and transcription [40,41]. Between different mammalian species, the mtDNA is
about the same size and has the similar organization and content of genes [42-44]. The
Understanding Mitochondrial DNA in Brain Tumorigenesis
http://dx.doi.org/10.5772/58965
7
mitochondrial genome has been sequenced and mapped for many species yet the regulation
of its expression is poorly understood.
The human mtDNA contains 37 genes coding mRNAs for 13 polypeptides that are part of four
of the five multi-enzymatic complexes in the OXPHOS system, 22 tRNAs (that are able to
decode all open reading frames) and 2 rRNAs (components of the specific mitochondrial
ribosomes) necessary for synthesis of the polypeptides. Unlike nuclear DNA, mtDNA coding
sequences have no introns. Seven of those polypeptides, ND1 to ND6 and ND4L are subunits
of Complex I; one, cytochrome b, is part of Complex III; three, COX I, COX II and COX III, are
the catalytic subunits of Complex IV, and ATPase 6 and 8 are subunits of Complex V (F0F1 ATP
synthase). The heavy strand is the main coding strand, and codes for 2 rRNAs, 14 tRNAs and
12 polypeptides. The light strand codes for remaining 8 tRNAs and only one polypeptide, the
ND6 subunit (NADH-dehydrogenase) [6].
Mammalian mitochondria are not self-supporting entities in the cell. Replication and tran‐
scription depend upon trans-acting nuclear-encoded factors. All proteins of mitochondrial
ribosomes and their associated translation factors and, indeed, all other mitochondrial proteins
including the components of the mitochondrial import machinery are encoded by the nuclear
DNA. For instance, mitochondrial tRNAs are charged by imported aminoacyl-tRNA synthe‐
tases from nuclear genes.
There are approximately hundreds or thousands copies of mitochondrial genome in each
somatic cell. Normally, all of the mitochondrial DNAs within the cells of an individual are
identical, which is termed homoplasmy. However, in the presence of a mitochondrial DNA
mutation, the affected individual cells will usually harbour a mixture of mutated and wild-
type mitochondrial DNA. The condition of these two populations of mitochondrial DNA
molecules is called heteroplasmy [45]. As cells divide, the mutant and wild-type mitochondrial
DNA are randomly distributed to the daughter cells, so the proportion of mutant to wild-type
mitochondrial DNA may increase or decrease with each subsequent generation of the cell line.
If that proportion increases past a certain level, the cellular energy capacity will decline, and
clinical signs appear. This is referred to as the threshold effect. The threshold may vary from
tissue to tissue because the percent of mutant mitochondrial DNA needed to cause cell
dysfunction varies according to the oxidative requirements of the tissue and the severity of
the mutation. It has often been claimed that tissues with high requirements for oxidative energy
metabolism, such as muscle and brain, have relatively low thresholds and are particularly
vulnerable to mitochondrial DNA mutation.
Human mitochondrial DNA is a 16,569 base pair circle of double-stranded DNA that encodes
13 essential respiratory chain subunits. ND1–ND6 and ND4L encode seven complex I (NADH–
ubiquinone oxidoreductase) subunits, CYT b encodes one subunit of complex III (ubiqui‐
nol:cytochrome c oxidoreductase), COX I–COX III encode the three major catalytic subunits
of complex IV, and ATPase6 and ATPase8 encode two subunits of complex V (ATP synthase).
Also shown are the two ribosomal RNA (12S rRNA and 16S rRNA) genes and the 22 transfer
RNA genes (red spheres, depicted by single letter amino acid code abbreviation) required for
mitochondrial protein synthesis. tRNAs are F, Phenylalanine; V, Valine; L, Leucine; I, Isoleu‐
cine; Q, Glutamine; M, Methionine; W, Tryptophan; A, Alanine; N, Asparagine; C, Cysteine;
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Y, Tyrosine; S, Serine; D, Aspartic acid; K, Lysine; G, Glycine; R, Arginine; H, Histidine; E,
Glutamic acid; T, Threonine; P, Proline. The genome is highly organised and shows little
redundancy of its coding sequence. The displacement loop (D-loop), or non-coding control
region contains the promoters for transcription of the L (LSP) and H strands (HSP1 and HS2)
and the origin of replication of the H strand (OH). The origin of light-strand replication is shown
as OL.
5. Warburg theory and mitochondrial dysfunction in cancer cells
In the 1930s, the German scientist, Dr. Otto H. Warburg pioneered the research specifically
targeted to the alterations of mitochondrial respiration in the aspect of cancer. He reported
that cancer cells exhibited a high glycolysis rate even in the presence of abundant oxygen. This
phenomenon was known as the “Warburg effect”. Cancer cells had to depend on anaerobic
glycolysis rather than respiration to generate ATP [46]. He further proposed that defects in
energy metabolism, especially due to mitochondrial malfunction, are involved in the initiation
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or progression of cancer. Dr. Warburg's discovery encouraged many scientists to realize the
potential role of mitochondria in cancer cells.
Since then, alterations of mitochondria in the number, shape and function have been reported
in various cancers [47]. The conversion of ATP production from mitochondrial OXPHOS to
glycolysis has been suggested to be the bioenergetic hallmark of cancer cells [48]. Furthermore,
it has been shown that mitochondrial dysfunction is able to initiate critical signaling pathways
that modulate cell proliferation or growth [49,50]. A study done by Pelicano’s group found
that mitochondrial respiration defects promoted to increased level of NADH, which could
inactivate PTEN via a redox modification mechanism [51]. PTEN deactivation could lead to
activation of the protein kinase B (Akt) survival pathway [51]. Akt was show to stimulate
glycolysis and also trigger an increase in cell survival of cancer cells [52,53]. In addition, Lopez-
Rios and colleagues showed that inhibition of OXPHOS activity by incubation of lung cancer
cells with oligomycin could trigger a rapid increase in aerobic glycolysis [54]. This finding
demonstrates that suppression of mitochondrial energy production can lead tumor cells
become glycolytic [54]. However, when glycolysis was inhibited, tumor cells were unable to
sufficiently upregulate mitochondrial OXPHOS and this indicating was due to partial mito‐
chondrial impairment [55].
6. Reactive Oxygen Spices (ROS) and tumorigenesis
ROS such as superoxide anion radical (O2¯), hydrogen peroxide (H2O2) and hydroxyl radical
(OH ) are constantly generated during metabolic process in all living species [56]. Mitochon‐
drial respiratory chain is a major intracellular source or producer of ROS generation, as some
of the electrons passing to molecular oxygen are instead leaked out of the chain. Under normal
physiological conditions, cellular ROS generation is counterbalanced by the action of the
endogenous systems include mainly antioxidant enzymes for instance superoxide dismutases
(SODs), cytosolic copper/zinc SOD (CuZnSOD) and mitochondrial manganese SOD (MnSOD).
Low levels of ROS regulate cellular signaling and are essential in proliferation of normal cell.
However, overproduction of ROS will lead to various cellular components injury, such as
damage to DNA, proteins and lipids. Recent studies have demonstrated a role of ROS in
promoting tumor development. The exposure of normal cells to ROS led to an increase in
proliferation [57] and expression of growth-related genes [58-60]. Furthermore, cancer cells
are commonly known to generate more ROS than normal cells [61,62]. These observations
suggest that the stimulation of ROS may be an important contributing factor in the initiation,
maintenance and development of cancer in vivo.
ROS are highly active and can also cause damage to mitochondrial genome [63,64]. It has been
proposed that damage to mtDNA, if not repaired properly, could initiate tumorigenesis and
promote cancer development [65,66]. Mutations in mtDNA may lead to a decreased efficiency
of the OXPHOS system and increased leakage electrons as well as enhanced more mitochon‐
drial and cellular ROS production. This situation may result in creating oxidative stress which
will further accumulate more total damage to mtDNA because the location of mtDNA is in
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close proximity to the ROS-generating electron transport system. Thus, it is possible that
persistent oxidative stress on cells may favour the neoplastic process through induction of
mtDNA damage which leads to mutations [67].
Moreover, in contrast to nDNA, mtDNA does not contain intronic sequences and not cover
up with protective proteins such as histones. Due to these reasons, it has been suggested that
most mtDNA mutations occur in coding sequences. However, more recent data shows that
mtDNA can be almost completely covered by the DNA binding protein Tfam (mitochondrial
transcription factor A) [68]. In addition, mtDNA also harbors limited effective DNA repair
mechanisms. All these conditions are believed may contribute to the increased sensitivity of
mitochondrial genome to damage, and ultimately leads to mutations. Whether mutations in
mtDNA are a cause or a consequence of cancer is still debatable and need to be worked out.
However, it is proven that mutations of mtDNA induced by oxidative damage could contribute
significantly to OXPHOS defects and genetic instability in tumours and thereby promoting a
higher propensity for tumour cell growth and progression [69]. This can be suggested that
mutation of mtDNA may worsen oxidative stress or vice versa.
7. Apoptosis and tumorigenesis
Apoptosis, also called programmed cell death, is a crucial physiological process in the
development and homeostasis of multicellular organisms which requires the involvement of
mitochondria. Mitochondria have long been recognized for their essential role in regulating
apoptotic signaling pathways [70,71]. Defects in apoptotic cell-death pathways are believed to
contribute to genomic instability and tumorigenesis [72]. Study recently conducted shows that
the mitochondrial respiratory chain has the ability to modulate apoptosis [73]. Respiratory
chain dysfunction has been shown to either promote or suppress apoptotic cell death, relying
on the specific alteration of electron flux [73]. Stimulation of ROS production can initiate
apoptosis in the mitochondria. Mitochondrial defects normally can lead to reduced phosphor‐
ylation with low ATP generation and high cytosolic calcium and theses situations become a
signal which triggers the apoptotic cell death [74]. Mitochondrial respiration defects in cancer
cells can lead to activation of the Akt survival pathway which promotes cell death resistance.
As mentioned earlier, this activation of Akt was suggested to result from increased level of
NADH and inactivation of PTEN through a redox modification mechanism [51]. More
interestingly, another study has elucidated the role of mitochondrial chaperones in modulating
mitochondrial function for the survival of cancer cells [75,76]. Molecular chaperone heat shock
protein 60 (Hsp60) was shown to orchestrate a broad cell survival program centered on
stabilization of mitochondria and also to restrain p53 function [75]. Another chaperone, Hsp90
and its mitochondrial-related molecule, TRAP-1, were suggested to interact with cyclophilin
D to suppress cell death [76].
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8. Mitochondrial DNA mutations in cancer
Over 300 mtDNA mutations and even more mtDNA deletions have been reported that are
associated with human diseases, since the first diseases caused by mtDNA damage were
described 25 years ago [77-79]. Diseases that have been shown to be linked with mitochondrial
dysfunction are diabetes mellitus, Parkinson’s disease, Alzheimer’s disease, epilepsy, sensor‐
ineural deafness and a variety of syndromes involving muscles and the central nervous system
as well as a variety of forms of cancer [80-83]. The same mutation or different mutations in the
same mtDNA gene may present with very different clinical manifestations, while the same
clinical phenotype may be caused by different mutations (DiMauro and Schon, 2003). A large
number of mtDNA mutations have been associated to a wide variety of clinical manifestations/
phenotypes of mitochondrial diseases include mitochondria encephalomyopathy, lactic
acidosis and stroke-like syndrome (MELAS), myoclonic epilepsy and ragged red fiber disease
(MERRF), Lebers hereditary optic neuropathy (LHON), Leigh’s syndrome, Kearns-Sayre
syndrome, chronic progressive external ophthalmoplegia (CPEO), neuropathy, ataxia, retinitis
pigmentosa (NARP).
Although the role of nDNA mutations in carcinogenesis is well established, the importance of
mtDNA alterations in the development and maintenance of cancers is only now beginning to
be focused by researchers. Alterations in mtDNA which may lead to OXPHOS system
destabilization seem to be particularly crucial because 13 proteins encoded by mtDNA are
essential for complex I, and III–V respiratory chain assembly and these enzymatic complexes
defects have been reported in human solid tumours [85]. There is considerable evidence
suggesting that mitochondria may serve as potential contributors to carcinogenesis even
though the exact mechanism of how mitochondria involved is still debatable and is not well-
documented. Thus, mtDNA is now being targeted organelle by an increasing number of
laboratories in order to investigate its potential role as biomarker for tumorigenesis in various
types of tissues [86,87].
DNA alterations in mitochondria are believed to become fast hotspots of cancer research.
Indeed, numerous mutations in mtDNA has now been observed in multiple cancer types
(88-90] since the first somatic mtDNA mutation was detected 15 years ago by Bert Vogelstein's
group in human colorectal cancer cells [91]. After these initial findings, mtDNA mutations or
alterations have also been identified in bladder cancer [92], breast cancer [93-96], esophageal
cancer [97-99], head and neck cancer [100], hepatocellular carcinoma [101-103], lung cancer
[104-106], ovarian cancer [107,108], prostate cancer [109-111], renal cancer [112], thyroid cancer
[113] and a number of blood cancers [114,115]. More recently, various types of molecular
abberations in mtDNA such as point mutations, polymorphisms, depletion, insertions,
microsatellite instability and changes in mtDNA copy number have been characterized
throughout the mitochondrial genome in human cancers [89,90,116].
Molecular Considerations and Evolving Surgical Management Issues in the Treatment of Patients with a Brain Tumor12
9. Somatic mitochondrial DNA alterations and brain tumors
Although there have been studies reporting about the association of mtDNA mutations with
brain tumors, it is still no clear evidence whether mitochondrial abnormalities are contributing
factors in brain tumorigenesis. Several types of somatic mtDNA alterations have been
identified in brain tumors. These mtDNA alterations include point mutations, deletions,
insertions, mtMSI (mitochondrial microsatellite instability) and copy number changes.
9.1. Point mutations
A number of studies have detected mtDNA point mutations in cancer of the brain and other
central nervous system, including gliomas, astrocytomas, gliomatosis cerebri, medulloblasto‐
ma, meningiomas, schwannomas, and neurofibromas [19,20,117-120]. Mitochondrial genome
somatic point mutations were most frequently found in the D-loop region, especially in a poly-
cytosine (poly-C) mononucleotide repeat tract located between 303 and 315 nucleotides known
as D310. This location has been identified as a hot spot region for somatic mtDNA mutations
in various human cancers, including in brain cancer. In 2005, Montanini’s groups analyzed the
D-loop region of mtDNA in 42 patients affected by malignant gliomas and found sequence
alterations in 36% of the patients including 16 somatic mutations, mostly in the D310 area. The
authors suggested that mtDNA mutations were easily amplified from post-surgical tumor
cavities and could be used for the clinical follow-up of malignant gliomas [121].
Instead of focusing on D-loop region, the complete of mitochondrial genome was also
examined by various researchers in brain cancer patients. In a study that involved the entire
mtDNA mutation scanning by temporal temperature gel electrophoresis (TTGE) in medullo‐
blastomas, 40% of the cases (6/15) were found to have at least one somatic mutation [20]. Seven
matched cerebrospinal fluid (CSF) samples were also analyzed to detect mtDNA mutations,
where some of them were harbored mtDNA mutations in the tumors. This study suggests that
somatic mtDNA mutations in CSF shows some promise as potentially useful biomarkers for
disease prognosis. On the other hand, Lueth’s group (2010) also reported the existence of
somatic mtDNA mutations in 6 of 15 medulloblastoma patients. These results are in support
of their previous findings on frequency of somatic mitochondrial mutations in medulloblas‐
toma [23]. Before investigation on medulloblastoma patients, Lueth and colleagues have
sequenced entire mitochondrial genome of tumor tissue and matched blood samples from 19
pilocytic astrocytomas patients and identified somatic mutations in as many as 16 (84%) cases
[22].
In the cases of neurofibromas, Kurtz and team (2004) analyzed the whole mitochondrial
genome in 37 neurofibromatosis type 1 patients and found somatic mutations in 7 individuals
with cutaneous neurofibromas (37%) and 9 patients with plexiform neurofibromas (50%) [119].
All of the mtDNA somatic mutations detected in this study occurred in the D-loop region. The
reason of most genetic mutations to occur in non-coding regions of the mitochondrial genome
is currently unknown. However, mutations in the D-loop are believed to influence the origin
of replication and promoter region and thus may lead to impair mitochondrial biogenesis and
defective transcription and protein expression [122,123].
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9.2. Deletion
Amongst the large-scale deletions identified in the mitochondrial genome, the 4977-bp
deletion is the most common mtDNA deletion detected in various types of cancers including
thyroid tumors, esophageal carcinoma, hepatocellular carcinoma, gastric cancer, and breast
cancer [124-128]. This deletion recognized as “common deletion” removes all 5 tRNA genes
and 7 genes encoding 4 complex I subunits, 1 complex IV subunit, 2 complex V subunits, which
are essential for maintaining normal mitochondrial OXPHOS function. The consequence of
this deletion could cause a complete failure of ATP production and abnormal ROS generation
[129]. Although the 4977-bp deletion has been implicated in the process of carcinogenesis, the
involvement or role of this deletion in brain tumors has not yet been investigated. Besides no
study to date on the brain tumors, Wallace’s group examined the existence of 4977-bp deletion
in the aging process using brain normal individuals [130]. They found a significant increase in
the 4977-bp deletion from young to old individuals, in different regions of the brain between
cortex, putamen and cerebellum. Therefore, it was suggested that this mtDNA deletion might
contribute to the neurological impairment associated with ageing. The 4977-bp deletion was
also detected in the autopsied brains of patients with bipolar disorder [131].
9.3. Mitochondrial microsatellite instability
In 1999, Kirches and colleagues revealed high mtDNA sequence variants in 12 astrocytic
tumors [117]. Two years later, the same group extended the study by examining 55 gliomas
specimens for mtDNA instability in the poly-C tract of mitochondrial D-loop using a combi‐
nation of laser microdissection and PCR technique [19]. They found a lower frequency of 9%
of specimens with the poly-C tract alterations. In addition, they also sequenced the entire D-
loop in 17 frozen glioblastoma samples and corresponding blood samples for detecting somatic
mutation. In 2003, a follow up study of mitochondrial genome instability was carried out and
the author later determined that poly-C tract of the hypervariable region (HVR2) as a clonal
marker in gliomatosis cerebri patients [118].
Most recently, Yeung’s team investigated the contribution of mitochondrial genome variants
in glioblastoma multiforme (GBM) [132]. In this study, mtDNA variants were analysed in a
series of GBM cell lines using a combination of next generation sequencing and high resolution
melt (HRM) analysis. They reported a greatest frequency of mtDNA variants in the D-loop
and origin of light strand replication in non-coding regions. Moreover, in coding region, ND4
and ND6 were the most affected genes to mutation which both of them encode subunits of
complex I of the electron transport chain. The author concluded that these novel variants at
the mitochondrial genome offer an advantage to cells for promoting GBM tumorigenesis [132].
9.4. Copy number changes
In addition to mtDNA mutations and deletion, changes in the mtDNA copy number have been
studied in gliomas [133,134]. As first previously reported by Liang (1996), 15 of low-grade were
assessed with cDNA homologous to mtDNA at position 1,679-1,946 and 2,017-2,057 and the
results revealed that these tumors had increased mtDNA copy number when compared to
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normal brain tissue controls [133]. In a separate study done by Liang and Hays (1999), 39 out
of 45 (87%) examined gliomas, both low-grade and high-grade specimens, had increased up
to 25-fold in mtDNA copy numbers [134]. They claimed that this frequency was much higher
than erb-b gene amplification which was present in only 18% of these tumors.
9.5. Mitochondrial gene expression changes
In 2005, Dmitrenko’s group screened cDNA libraries of human fetal glioblastoma and normal
human brain samples and revealed 80 differentially expressed genes [135]. They identified 30
were corresponded to mitochondrial genes for ATP6, COXII, COXIII, ND1, ND4 and 12S
rRNA. According to their data, all these mitochondrial transcripts were expressed at lower
level in glioblastomas as compared to tumor-adjacent histologically normal brain [135].
10. Conclusion
The role of mtDNA mutations in cancer remains largely unclear and therefore more studies
and attentions should been given before a clear conclusion could be achieved. There is a lot of
evidence suggesting that some mtDNA mutations do play a role in certain stages of cancer
development and progression, but further research is needed to clarify this possible link. There
are still multiple potential experimental pitfalls and weaknesses, thus relevant caution and
basic guidelines in research should be followed in order to obtain the best results [136,137].
Based on our ongoing research and previous studies from other researchers, it could be
suggested that mtDNA mutations could be a genetic aberration target in cancer development,
instead of nuclear oncogenes and tumor suppressor genes. Cancer cells are very mutagenic in
the early stage either due to exposure to high levels of carcinogenic substances or conditions
or because of lack of repair mechanism. Thus, mtDNA simply seem to be more prone to
mutation at this stage and has a limited ability to repair itself.
Mitochondria produce energy and their genome is responsible for regulating OXPHOS
function. Aberrations in mtDNA may interrupt this process and ultimately lead to abnormal
function of the cell. The unique properties of mtDNA, including its high copy number, high
susceptibility to mutations, and quantitative and qualitative changes in cancer, stimulate
researchers to closely be involved in the clinical relevance investigation of mtDNA alterations
in cancers. In addition, the screening of mtDNA mutations is more easy and cost-effective than
nDNA analysis, due to several advantages that mtDNA have such as a simple circular structure
with a short sequence length. It has been shown that the existence of mtDNA mutations in
cancer cells is particularly consistent with the intrinsic sensitivity of mtDNA to accumulate
oxidative damage. Impairment of mitochondrial OXPHOS activity and mtDNA damage seem
to be a common feature of malignant cells. Instability and abnormality in DNA and protein of
mitochondria have been identified in various solid tumors and hematologic malignancies.
However, up to now many studies have been directed toward identifying and characterizing
the altered mtDNA. There have been only limited studies, mainly in relation to its functional
consequences and clinical relevance. The functional aspects of mtDNA mutations in cancer
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development will provide a mechanistic link between mitochondria and carcinogenesis and
also will translate into some useful prevention and therapeutic strategies of cancer in the future
research.
Although to date mutations, polymorphisms, and variants of mtDNA have been described in
brain tumors, there are more studies that need to be done to fully understand the role of
mtDNA in these tumor cells. Further studies which include the assessment of the different
types and stages of brain tumor need to be carried out. It is very crucial because perhaps that
only certain stages and types will be sensitive to the effects of mtDNA mutations. Based on
available evidence suggests that mtDNA may play a key role in the development and modu‐
lation of different steps of carcinogenesis. They could be used in the future as new potential
target markers for rapid and effective early detection of brain tumorigenesis.
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